NCT01059552

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Fox Chase Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

Detailed description

This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC) vorinostat to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of 70Gy in NSCLC patients with unresectable IIIA and dry IIIB disease. The endpoint will be to determine MTD of the combination.

Conditions

• Locally Advanced Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	vorinostat	vorinostat once daily for 12 weeks of therapy

Timeline

• Start date: 2009-12-16
• Primary completion: 2015-07-22
• Completion: 2019-10-21
• First posted: 2010-02-01
• Last updated: 2019-11-27

Locations

3 sites across 1 country: United States